Several TNF‐α‐inhibiting antibodies have been developed and tested as potential therapy options for retinal degenerations including preclinical models for AMD, glaucoma, and ischemic retinopathy (Al‐Gayyar & Elsherbiny, 2013). Here, TNF is linked to age-related macular degeneration.